Trial NC-HEM-14-4


Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open-label Study with Multiple and (for non-responders) Escalating Subcutaneous Doses of BI 655064 Once a week in Patients with Chronic Primary Immune Thrombocytopenic Purpura

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Howard Liebman, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Ibrahim Syed, Coordinator, Melissa Peralta, D.M., Niranjan Bhatt, D.M., Sondra Ortiz, R.N., Teresa Olea, R.N., Donna Fernando, R.N.

Staff may log in to see study documents.







For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.